Activation culture and proliferation of natural killer cells from non-small cell lung cancer patients
Main Article Content
Abstract
Autologous natural-killer -cell (NK cell)-based immunotherapy has been an efficacious and safe treatment method for various types of cancer, including lung cancer. The purpose of this study was to apply the process of extraction, activation, and proliferation of NK cells in non-small cell lung cancer in patients (NSCLC). The study was conducted on five healthy volunteers and five NSCLC patients. NK cells were isolated, activated, proliferated, and evaluated from 10 ml of blood sample of each participant. Among the five healthy volunteers, the number of NK cells isolated from 10 ml of peripheral blood was (11.74 ± 1.50) x 106 cells, and the cell survival rate was 93.6 ± 1.52%. The number of cells after 21-day culture was (11.1 ± 2.4) x 108, the cell survival rate was 78.05 ± 3.5%, and the survival rate of NK cells was 62.19±1.51%; the number of NK cells increased 674.93 ± 309.13 times. Among the five NSCLC patients, the number of NK cells isolated from 10 ml peripheral blood was (9.88 ± 1.10) x 106 cells, and the cell survival rate was 94.6 ± 0.89%. The number of cells after 21-day culture was (9.43 ± 1.08) x 108, the cell survival rate was 78.05 ± 3.5%, and the survival rate of NK cells was 59.56 ± 3,43%; the number of NK cells increased 644.43 ± 298.12 times. There was no difference between the healthy group and the NSCLC group in the increase in the number of NK cells (p = 0.878).
Article Details
Keywords
Autologous NK-cell-based immunotherapy, NK cells, non-small cell lung cancer in patients (NSCLC).
References
2. 704-viet-nam-fact-sheets.pdf. Accessed July 1, 2020. https://gco.iarc.fr/today/data/factsheets/populations/704-viet-nam-fact-sheets.pdf.
3. Khoa MT. Kháng thể đơn dòng và phân tử nhỏ trong điều trị bệnh ung thư. Nhà xuất bản Y học. Published online 2016.
4. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cellular & Molecular Immunology. 2013;10(3):230-252. doi:10.1038/cmi.2013.10.
5. Iliopoulou EG, Kountourakis P, Karamouzis MV, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother. 2010;59(12):1781-1789. doi:10.1007/s00262-010-0904-3.
6. Farag SS, Caligiuri MA. Human natural killer cell development and biology. Blood Reviews. 2006;20(3):123-137. doi:10.1016/j.blre.2005.10.001.
7. hilds RW, Berg M. Bringing natural killer cells to the clinic: ex vivo manipulation. Hematology Am Soc Hematol Educ Program. 2013;2013(1):234-246. doi:10.1182/asheducation-2013.1.234.
8. Poznanski SM, Lee AJ, Nham T, et al. Combined Stimulation with Interleukin-18 and Interleukin-12 Potently Induces Interleukin-8 Production by Natural Killer Cells. JIN. 2017;9(5):511-525. doi:10.1159/000477172.
9. Grievink HW, Luisman T, Kluft C, Moerland M, Malone KE. Comparison of Three Isolation Techniques for Human Peripheral Blood Mononuclear Cells: Cell Recovery and Viability, Population Composition, and Cell Functionality. Biopreserv Biobank. 2016;14(5):410-415. doi:10.1089/bio.2015.0104.
10. Granzin M, Soltenborn S, Müller S, et al. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy. Cytotherapy. 2015;17(5):621-632. doi:10.1016/j.jcyt.2015.03.611.
11. Koehl U, Sörensen J, Esser R, et al. IL-2 activated NK cell immunotherapy of three children after haploidentical stem cell transplantation. Blood Cells, Molecules, and Diseases. 2004;33(3):261-266. doi:10.1016/j.bcmd.2004.08.013.
12. Carlens S, Gilljam M, Chambers BJ, et al. A new method for in vitro expansion of cytotoxic human CD3−CD56+ natural killer cells. Human Immunology. 2001;62(10):1092-1098. doi:10.1016/S0198-8859(01)00313-5.
13. Berg M, Childs R. Ex-vivo expansion of NK cells: What is the priority - high yield or high purity? Cytotherapy. 2010;12(8):969-970. doi:10.3109/14653249.2010.536216.
14. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106(1):376-383. doi:10.1182/blood-2004-12-4797.
15. Lapteva N, Durett Ag, Sun J, et al. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 2012;14(9):1131-1143. doi:10.3109/14653249.2012.700767.
16. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA. Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression. Clin Cancer Res. 2011;17(19):6287-6297. doi:10.1158/1078-0432.CCR-11-1347.
17. Berg M, Lundqvist A, Jr PM, et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009;11(3):341-355. doi:10.1080/14653240902807034.
18. Siegler U, Meyer-Monard S, Jörger S, et al. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. Cytotherapy. 2010;12(6):750-763. doi:10.3109/14653241003786155.
19. Curti A, Ruggeri L, D’Addio A, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood. 2011;118(12):3273-3279. doi:10.1182/blood-2011-01-329508.
20. Alici E, Sutlu T, Björkstrand B, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 2008;111(6):3155-3162.doi:10.1182/blood-2007-09-110312.